Steve Gillies, PhD

Chief Scientfic Officer, Alopexx Oncology

Dr. Gillies is an expert in the creation and development of recombinant antibodies and immunotherapies. Currently he serves as both the CSO of Alopexx Oncology and as the Founder and CEO of Provenance Biopharmaceuticals corp. Prior to founding Provenance, Dr. Gillies led all scientific and business endeavors of Lexigen Pharmaceuticals Corp. After Lexigen’s acquisition in 1999 by Merck KGaA, Dr. Gillies had the additional responsibility of overseeing Merck’s Global Oncology Pre-clinical research. Previously, he was Vice President of research at Damon Biotech and Abbott Biotech Inc., where he oversaw development of recombinant antibodies and pro-urokinase, an anti-clotting protein. As a postdoctoral fellow at the Massachusetts Institute of Technology, he identified the first cellular enhancer sequences that were found to be critical for the regulation of antibody expression. This discovery proved a key part of the commercial success of Erbitux, a cancer drug marketed by Eli Lilly, Bristol Myers Squibb, and Merck KGaA. A second antibody created by Dr. Gillies at Damon Biotech gained market approval in March 2015 for treatment pediatric neuroblastoma. As part of his recombinant antibody project work, Dr. Gillies invented and developed immunocytokine (antibody-cytokine fusion protein) technology, and leveraged through his academic network, the first clinical proof of concept of this approach. Dr. Gillies received his M.S. degree and Ph.D. in Microbiology from the College of Medicine and Dentistry, Rutgers University and his B.S. degree in Microbiology from the University of Massachusetts, Amherst.